Prof Barbara Eichhorst (University Hospital Cologne, Cologne, Germany) discusses the impact of venetoclax plus obinutuzumab on the treatment of patients with chronic lymphocytic leukaemia (CLL) who are unfit for chemoimmunotherapy.
The abstract ‘TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL’ (Abstract: LB2365) was presented at the EHA2022 Congress, 9-12 June 2022.
Questions
- What has been the impact of venetoclax plus obinutuzumab on the treatment of patients with chronic lymphocytic leukaemia (CLL) who are unfit for chemoimmunotherapy? (00:20-00:58)
- What did the GAIA/CLL13 study teach us about the impact of venetoclax and obinutuzumab in fit patients with CLL? (00:58-01:42)
- What were the objectives of the current analysis? (01:42-02:18)
- What were the findings in terms of progression-free survival? (02:18-03:27)
- What will be the impact of these findings on the treatment paradigm for CLL? (01:27-04:31)
Disclosures: Barbara Eichhorst is a consultant for: Almirall, Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche and Sandoz. She has received grant/research support from: Biogen, Research Fund Flanders, Charcot Foundation Belgium, Merck, Sanofi-Genzyme and Roche. She is on the advisory board for: Almirall, Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche and Sandoz.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA)
